Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Companyâs XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.

Employees

3,620

Sector

Advanced Medical Equipment & Technology

Calendar

Aug. 04 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-07-10	29.77 $	-0.57%	303,144
25-07-09	29.94 $	+0.94%	287,497
25-07-08	29.66 $	+2.56%	505,675
25-07-07	28.92 $	-3.08%	415,819
25-07-03	29.84 $	+0.13%	185,031

Delayed Quote Nasdaq, July 10, 2025 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

29.77USD

Average target price

43.00USD

Spread / Average Target

+44.44%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-10 pm EDT			5-day change	1st Jan Change
29.77 ^USD	-0.57%		-0.23%	-33.13%

Jun. 30	Omnicell, Inc.(NasdaqGS:OMCL) dropped from Russell 2000 Value-Defensive Index	CI
Jun. 30	Omnicell, Inc.(NasdaqGS:OMCL) dropped from Russell 2000 Defensive Index	CI

Capitalization	1.39B 1.19B 1.11B 1.03B 1.91B 120B 2.12B 13.29B 5.08B 55.87B 5.23B 5.12B 204B	P/E ratio 2025 *	-292x	P/E ratio 2026 *	216x
Enterprise value	1.39B 1.19B 1.11B 1.03B 1.91B 120B 2.12B 13.29B 5.08B 55.87B 5.23B 5.12B 204B	EV / Sales 2025 *	1.23x	EV / Sales 2026 *	1.19x
Free-Float	80.46%	Yield 2025 *	-	Yield 2026 *	-

Omnicell, Inc.(NasdaqGS:OMCL) dropped from Russell 2000 Value-Defensive Index	Jun. 30	CI
Omnicell, Inc.(NasdaqGS:OMCL) dropped from Russell 2000 Defensive Index	Jun. 30	CI
Piper Sandler Adjusts Omnicell Price Target to $57 From $46, Maintains Overweight Rating	May. 23	MT
Omnicell, Inc. authorizes a Buyback Plan.	May. 22	CI
Omnicell, Inc. announces an Equity Buyback for $75 million worth of its shares.	May. 22	CI
Omnicell Updates Q2, 2025 Earnings Guidance, Approves New $75 Million Share Buyback Plan	May. 22	MT
Tranche Update on Omnicell, Inc.'s Equity Buyback Plan announced on August 5, 2016.	May. 22	CI
(OMCL) OMNICELL INC. Forecasts Fiscal Year 2025 Revenue Range $1.11B - $1.16B	May. 22	MT
Omnicell, Inc. Opens New Innovation Lab in Austin, Texas	May. 14	CI
Omnicell, Inc. Announces New Products Designed to Streamline Workflows and Enhance Inventory Visibility and Management in Perioperative and Clinic Settings	May. 14	CI
Omnicell Opens Innovation Lab in Texas	May. 14	MT
Wells Fargo Upgrades Omnicell to Overweight From Equal Weight, Adjusts Price Target to $35 From $31	May. 14	MT
Omnicell's Q1 Non-GAAP Net Income, Revenue Rise; 2025 Adjusted Earnings Guidance Reduced	May. 06	MT

Piper Sandler Adjusts Omnicell Price Target to $57 From $46, Maintains Overweight Rating	May. 23	MT
Wells Fargo Upgrades Omnicell to Overweight From Equal Weight, Adjusts Price Target to $35 From $31	May. 14	MT
BofA Securities Adjusts Price Target on Omnicell to $46 From $54	Jan. 06	MT
BofA Securities Downgrades Omnicell to Neutral From Buy, Adjusts Price Target to $57 From $44	24-10-31	MT
Barclays Upgrades Omnicell to Equalweight From Underweight, Adjusts Price Target to $39 From $26	24-08-02	MT

Omnicell, Inc. Stock

Equities

OMCL

US68213N1090

Advanced Medical Equipment & Technology

Valuation: Omnicell, Inc.

Chart: Omnicell, Inc.

Latest news: Omnicell, Inc.

Last Transcript: Omnicell, Inc.

Analysts' recommendations: Omnicell, Inc.

Press Releases: Omnicell, Inc.

News in other languages: Omnicell, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Omnicell, Inc.

ETFs: Omnicell, Inc.

Medical Software & Technology Services

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Omnicell : OmniSphere Receives HITRUST CSF (Common Security Framework) i1 Certification	Jun. 26	PU
Omnicell Expects Improved Profitability, Updates Second Quarter and Full Year 2025 Profit Outlook and Announces a New Stock Repurchase Program	May. 22	BU
Omnicell : Webcast 2025 Annual Meeting of Stockholders, May 21, 2025,	May. 21	PU
Omnicell Announces New Products for Perioperative and Clinic Settings	May. 14	BU
Omnicell Opens New Innovation Lab in Austin, Texas	May. 14	BU

USA-Les valeurs à suivre à Wall Street (actualisé)	22-07-15
Omnicell : kooperiert im Rahmen der Ausweitung der Omnicell-Systeme im gesamten South East London NHS Integrated Care System mit dem Guy's and St Thomas' NHS Foundation Trust, London, bei der Entwicklung eines europäischen, technologiegestützten...	21-01-05
Omnicell : s’associe au Guy’s and St Thomas’ NHS Foundation Trust de Londres pour le développement d’un centre européen de veille technologique, dans le cadre de l’expansion des systèmes d’Omnicell dans l’ensemble du South East London NHS Integrated...	21-01-05
Quels ETF choisir pour investir dans les valeurs moyennes ?	21-01-04
USA-Les valeurs à suivre à Wall Street (actualisé)	20-12-09

1 day	-0.57%
1 week	-0.23%
Current month	+1.26%
1 month	-4.71%
3 months	-4.21%
6 months	-29.59%
Current year	-33.13%

1 week	28.81	30.55
1 month	27.7	30.57
Current year	22.66	47.69
1 year	22.66	55.74
3 years	22.66	117.56
5 years	22.66	187.28
10 years	22.66	187.28

Manager	Title	Age	Since
Randall Lipps CEO	Chief Executive Officer	67	2002-09-30
Nchacha Etta DFI	Director of Finance/CFO	54	2023-05-31
Perry Genova CTO	Chief Tech/Sci/R&D Officer	-	2025-03-30

Director	Title	Age	Since
Randall Lipps CHM	Chairman	67	1992-08-31
Mark Parrish BRD	Director/Board Member	69	2012-12-31
Joanne Bauer BRD	Director/Board Member	69	2013-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
OMNICELL, INC.	-0.57%	-0.23%	+16.24%	-74.46%	1.39B
VEEVA SYSTEMS INC.	-0.96%	-0.34%	+54.55%	+34.08%	46.02B
PRO MEDICUS LIMITED	-0.11%	+3.24%	+137.39%	+595.16%	21.78B
SECTRA AB	+0.36%	+2.52%	+50.55%	+129.28%	7.21B
XUNFEI HEALTHCARE TECHNOLOGY CO., LTD.	-0.10%	-3.16%	-	-	1.56B
EVOLENT HEALTH, INC.	-0.53%	-4.26%	-41.23%	-66.45%	1.3B
RAYSEARCH LABORATORIES AB	+0.28%	+2.16%	+159.88%	+452.10%	1.27B
B-SOFT CO.,LTD.	-0.73%	-1.97%	+69.04%	-22.33%	1.18B
LUNIT INC.	-0.62%	-8.60%	-0.21%	-	1.01B
SURGICAL SCIENCE SWEDEN AB	-1.91%	-3.62%	+17.14%	-1.46%	813M
Average	-0.50%	+0.41%	+51.48%	+130.74%	8.35B
Weighted average by Cap.	-0.58%	+2.61%	+74.82%	+195.38%

	2025 *	2026 *
Net sales	1.13B 968M 902M 834M 1.55B 97.03B 1.72B 10.79B 4.12B 45.34B 4.24B 4.16B 166B	1.17B 1B 936M 865M 1.61B 101B 1.79B 11.19B 4.27B 47.02B 4.4B 4.31B 172B
Net income	-4.84M -4.14M -3.86M -3.57M -6.63M -415M -7.38M -46.18M -17.64M -194M -18.17M -17.79M -709M	7.56M 6.47M 6.02M 5.57M 10.34M 648M 11.51M 72.03M 27.51M 303M 28.34M 27.76M 1.11B
Net Debt	-	-